Clinical-stage biopharmaceutical company developing novel antibody-based therapies for pediatric and adult cancers.
Y-mAbs Therapeutics, Inc. is a pioneering biopharmaceutical company operating at the forefront of cancer treatment in the United States. Specializing in the development and commercialization of innovative antibody-based therapeutic products, Y-mAbs focuses primarily on addressing unmet medical needs in oncology. Central to its portfolio is DANYELZA, a monoclonal antibody co-formulated with granulocyte-macrophage colony-stimulating factor, approved for treating pediatric patients with relapsed or refractory high-risk neuroblastoma.
Beyond its current offerings, Y-mAbs is actively advancing its pipeline with promising candidates. This includes further developing DANYELZA for use in first-line neuroblastoma treatment, as well as exploring its potential applications in third-line neuroblastoma and relapsed osteosarcoma through ongoing Phase II clinical trials. Additionally, the company is progressing GD2-GD3 vaccine and Omburtamab, both undergoing clinical evaluation for treating various cancers such as Stage 4 high-risk neuroblastoma and CNS/leptomeningeal metastases.
Y-mAbs's commitment to innovation extends to its development of Nivatrotamab, targeting small cell lung cancer, and Lu-omburtamab-DTPA, aimed at medulloblastoma and B7-H3 positive leptomeningeal metastases. These efforts are bolstered by strategic partnerships, including license agreements with prestigious institutions like Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology, facilitating the advancement and commercialization of licensed products.
Founded in 2015 and headquartered in New York, New York, Y-mAbs Therapeutics continues to drive forward with a strong dedication to transforming cancer therapy. By leveraging cutting-edge science and collaborative partnerships, the company remains steadfast in its mission to improve outcomes for patients facing challenging oncological conditions world wide.